Loading company…
Aglaia Therapeutics develops medicines for cancer patients who develop resistance to targeted therapies.
Based in France, Aglaia Therapeutics develops oncology therapies intended to restore sensitivity to targeted treatments in patients who develop resistance. The company was co-founded by Advent France Biotechnology, Alejo Chorny, Institut Curie and Gustave Roussy. In September 2021, it raised Seed funding from Advent France Biotechnology, Crédit Mutuel Innovation and Pierre Fabre to prepare its preclinical program.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in